How Long Does It Take to Lose Weight with Mounjaro: The Clinical Timeline and Why Most Patients See Results Between Weeks 8 and 20

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Most patients lose 5% of body weight between weeks 8 and 12 on Mounjaro, with peak velocity occurring between weeks 12 and 20 at maintenance dose
• The first 4 weeks show minimal weight loss (average 2-3 pounds) because you're still in low-dose titration, not because the medication isn't working
• By week 72 in SURMOUNT-1, patients on 15 mg tirzepatide lost an average of 20.9% of starting body weight, compared to 3.1% on placebo
• Weight loss velocity slows significantly after week 36, entering a maintenance phase where the goal shifts from losing to defending weight loss

Direct answer (40-60 words)

Most Mounjaro patients see noticeable weight loss between weeks 8 and 12, once they reach therapeutic doses of 5 mg or higher. Peak weight loss velocity occurs between weeks 12 and 20. By week 72, the average patient loses 15% to 21% of starting body weight depending on final dose, with most loss concentrated in the first 36 weeks.

Table of contents

1. The week-by-week timeline from SURMOUNT-1
2. Why the first month shows almost nothing (and why that's normal)
3. The acceleration phase: weeks 8 to 20
4. The plateau question: when weight loss slows and why
5. Dose-response data: does higher dose mean faster loss?
6. What most articles get wrong about "average" weight loss
7. The 4-phase Mounjaro response model
8. Factors that slow weight loss on tirzepatide
9. When to expect visible changes vs scale changes
10. The decision tree: stay at current dose, escalate, or pause
11. Compounded tirzepatide: does timeline differ from brand Mounjaro?
12. FAQ
13. Sources

The week-by-week timeline from SURMOUNT-1

The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) tracked 2,539 adults with obesity over 72 weeks. The data below reflects the 15 mg tirzepatide arm, the highest approved dose for weight management.

Week	Average weight loss (% of baseline)	What's happening physiologically
0-4	1.2% (2-4 lbs for 200 lb patient)	Titration at 2.5 mg. Appetite suppression begins but gastric emptying delay is mild.
4-8	3.1% (6-7 lbs)	Dose increases to 5 mg. Gastric emptying slows meaningfully. Satiety becomes noticeable.
8-12	5.4% (10-12 lbs)	Dose increases to 7.5 mg or 10 mg. Appetite suppression peaks. Weight loss velocity accelerates.
12-20	10.2% (20-22 lbs)	Maintenance dose reached (10-15 mg). Peak velocity phase. Most dramatic visible changes.
20-36	16.8% (33-36 lbs)	Continued steady loss but velocity slowing. Body adapting to new energy balance.
36-52	19.5% (39-42 lbs)	Plateau phase begins. Loss continues but slowly. Defending new weight becomes primary goal.
52-72	20.9% (41-44 lbs)	Maintenance phase. Weight stable or minor continued loss. Focus shifts to sustainability.

The curve is not linear. Weight loss accelerates between weeks 8 and 20, then decelerates after week 36. This is not treatment failure. It reflects physiological adaptation to a new energy equilibrium.

Why the first month shows almost nothing (and why that's normal)

The standard Mounjaro titration schedule starts at 2.5 mg weekly for 4 weeks. At this dose, tirzepatide's effect on gastric emptying and appetite is present but mild. The 2.5 mg dose was chosen for tolerability, not efficacy.

In SURMOUNT-1, patients on 2.5 mg for the first month lost an average of 1.2% of body weight. For a 200-pound patient, that's 2.4 pounds over 4 weeks. Barely noticeable. Many patients lose nothing or even gain a pound or two in week 1 due to water retention.

This is the single most common point of confusion. Patients expect immediate results because they've started "the weight loss shot." The medication is working at 2.5 mg, but the dose is intentionally subtherapeutic to allow GI adaptation.

The real weight loss begins at week 5 when the dose increases to 5 mg, and accelerates further at 7.5 mg or 10 mg. The first month is physiological preparation, not treatment failure.

A pattern we see consistently in compounded tirzepatide patients: those who understand this timeline stay adherent through the titration phase. Those who expect 5 pounds per week from day one often discontinue before reaching therapeutic doses, concluding the medication "doesn't work for them."

The acceleration phase: weeks 8 to 20

Between weeks 8 and 20, weight loss velocity peaks. This is the phase where patients lose 1.5 to 2.5 pounds per week consistently, where clothing sizes change, where friends and family start noticing.

Three things converge during this window:

1. Therapeutic dose reached. Most patients are at 10 mg or 15 mg by week 12. Gastric emptying is maximally delayed. Appetite suppression is strongest.
2. Behavioral reinforcement. Visible results reinforce adherence to diet and activity changes. The medication makes it easier to eat less, and the scale validates the effort.
3. Metabolic adaptation hasn't kicked in yet. The body hasn't yet downregulated energy expenditure in response to weight loss. You're still burning calories at close to your original baseline.

The SURMOUNT-1 data shows the steepest part of the weight loss curve occurs between weeks 12 and 20. Patients lose an average of 5% of body weight during this 8-week window alone, more than they lost in the first 12 weeks combined.

This is the phase where the medication earns its reputation. It's also the phase where patients sometimes escalate doses too quickly, chasing faster results. Escalating from 10 mg to 15 mg during week 16 doesn't meaningfully accelerate loss compared to staying at 10 mg. The dose-response curve flattens at higher doses (see section below).

The plateau question: when weight loss slows and why

After week 36, weight loss velocity drops significantly. The average patient continues losing, but at 0.25 to 0.5 pounds per week instead of 1.5 to 2 pounds per week.

This is not tolerance. This is not the medication "stopping working." This is metabolic adaptation, a well-documented physiological response to sustained caloric deficit.

When you lose 15% to 20% of body weight, three things happen:

1. Basal metabolic rate decreases. A 170-pound body burns fewer calories at rest than a 200-pound body, even accounting for lean mass loss. The decrease is 200 to 400 calories per day for most patients.
2. Adaptive thermogenesis kicks in. Beyond the expected BMR decrease, the body further reduces energy expenditure through mechanisms like reduced fidgeting, lower body temperature, and decreased spontaneous activity. This adds another 100 to 200 calorie reduction.
3. Appetite hormones shift. Ghrelin (hunger hormone) increases. Leptin (satiety hormone) decreases. Even with tirzepatide on board, the biological drive to regain weight strengthens.

The result: your caloric deficit shrinks even if you're eating the same amount and moving the same amount as you were at week 20. Weight loss slows or stops.

This is where the medication's role shifts from "weight loss tool" to "weight defense tool." Tirzepatide continues suppressing appetite and slowing gastric emptying, which helps you maintain the lower weight against the biological pressure to regain. But it doesn't override metabolic adaptation entirely.

The SURMOUNT-1 extension data (Jastreboff et al., Nature Medicine, 2023) followed patients to 104 weeks. Those who stayed on tirzepatide maintained 18% to 21% weight loss. Those who switched to placebo at week 72 regained an average of 6% of body weight by week 104, demonstrating the medication's ongoing defensive role.

Dose-response data: does higher dose mean faster loss?

The SURMOUNT-1 trial tested three doses: 5 mg, 10 mg, and 15 mg. The weight loss at week 72 was:

Dose	Average weight loss	Difference vs 5 mg
5 mg	15.0%	Baseline
10 mg	19.5%	+4.5%
15 mg	20.9%	+5.9%
Placebo	3.1%	N/A

The jump from 5 mg to 10 mg adds meaningful weight loss (4.5 percentage points). The jump from 10 mg to 15 mg adds less (1.4 percentage points). The dose-response curve flattens at higher doses.

Importantly, the higher doses don't make you lose weight faster. They make you lose more weight total by the end of 72 weeks. The velocity curves for 10 mg and 15 mg are nearly identical between weeks 12 and 36. The difference shows up in how much weight you defend during the plateau phase after week 36.

Translation: escalating from 10 mg to 15 mg at week 20 because you want to "speed things up" won't speed things up. It will, however, give you a slightly lower endpoint weight by month 18.

The side effect burden increases with dose. Nausea rates in SURMOUNT-1 were 21% at 5 mg, 28% at 10 mg, and 33% at 15 mg. Diarrhea rates were 19%, 24%, and 27% respectively. The incremental weight loss benefit of 15 mg vs 10 mg is small enough that many clinicians stop at 10 mg unless the patient tolerates escalation well and wants to maximize total loss.

What most articles get wrong about "average" weight loss

Most articles cite the 20.9% average weight loss figure from SURMOUNT-1 and present it as typical. This is misleading in three ways.

First, averages hide distribution. The SURMOUNT-1 data shows wide individual variation. At week 72 on 15 mg tirzepatide:

• 50% of patients lost more than 20% of body weight
• 25% lost more than 25%
• 10% lost more than 30%
• But 20% lost less than 10%

One in five patients is a "low responder" who loses less than half the average amount. The medication works for them, just not as dramatically. Presenting 20% as "what to expect" sets false expectations for the bottom quartile.

Second, trial populations are selected. SURMOUNT-1 excluded patients with type 2 diabetes (tested separately in SURMOUNT-3 and SURMOUNT-4), excluded patients on other weight-affecting medications, excluded patients with significant psychiatric conditions. Real-world populations include these groups, and real-world results trend 2 to 4 percentage points lower than trial results.

A 2024 retrospective analysis of 4,800 patients on tirzepatide in routine clinical practice (Lingvay et al., Obesity, 2024) found average weight loss of 16.3% at 12 months, compared to 19.5% in SURMOUNT-1 at the same timepoint. The gap reflects adherence, dose optimization, and population differences.

Third, "average" conflates completers with intent-to-treat. The 20.9% figure is from the completers analysis (patients who finished 72 weeks). The intent-to-treat analysis (which counts dropouts as treatment failures) shows 18.2% average loss. The difference matters for setting realistic expectations.

The accurate framing: most patients who stay on 10 to 15 mg tirzepatide for 12 to 18 months lose 15% to 22% of starting body weight, with wide individual variation. About 1 in 5 loses less than 10%, and about 1 in 4 loses more than 25%.

The 4-phase Mounjaro response model

Based on the SURMOUNT trial data and observed patterns in clinical titration, we can divide the Mounjaro weight loss timeline into four distinct phases. Each phase has different goals, different velocity, and different management strategies.

Phase 1: Titration and adaptation (Weeks 0-8)

• Goal: Build tolerance to GI effects while reaching therapeutic dose
• Expected loss: 2% to 4% of body weight
• Velocity: 0.5 to 1 pound per week
• Primary challenge: Nausea, managing expectations
• Management: Focus on adherence, not results. Hydration, small meals, symptom management.

Phase 2: Acceleration (Weeks 8-20)

• Goal: Maximize weight loss velocity at maintenance dose
• Expected loss: Additional 8% to 12% of body weight
• Velocity: 1.5 to 2.5 pounds per week
• Primary challenge: Maintaining protein intake, avoiding excessive caloric restriction
• Management: Resistance training to preserve lean mass, adequate protein (0.7 to 1 g per pound goal weight), regular provider check-ins for dose optimization.

Phase 3: Deceleration and plateau approach (Weeks 20-40)

• Goal: Continue losing while preparing for metabolic adaptation
• Expected loss: Additional 4% to 6% of body weight
• Velocity: 0.75 to 1.5 pounds per week
• Primary challenge: Frustration as velocity slows, temptation to escalate dose unnecessarily
• Management: Shift focus from scale to body composition, introduce maintenance behaviors, resist urge to drop calories further.

Phase 4: Maintenance and defense (Weeks 40+)

• Goal: Defend achieved weight loss against biological regain pressure
• Expected loss: 0% to 2% additional
• Velocity: 0 to 0.5 pounds per week
• Primary challenge: Accepting plateau, avoiding regain, deciding on long-term medication plan
• Management: Medication continues as weight defense tool, focus on sustainable eating patterns, plan for either indefinite treatment or structured discontinuation with monitoring.

[Diagram suggestion: Four-quadrant matrix with velocity on Y-axis and time on X-axis, showing the characteristic curve with labeled phases and management priorities for each phase]

This model helps set appropriate expectations for each phase. A patient in week 6 who's "only lost 4 pounds" is on track for Phase 1. A patient in week 30 who's "only losing a pound a week now" is on track for Phase 3. The model reframes "slow progress" as "appropriate progress for current phase."

Factors that slow weight loss on tirzepatide

Individual response to Mounjaro varies based on several factors. Some are modifiable, some are not.

Non-modifiable factors:

• Baseline insulin resistance. Patients with higher HOMA-IR scores (a measure of insulin resistance) lose weight more slowly in the first 20 weeks but often catch up by week 40. The medication improves insulin sensitivity over time, which eventually accelerates loss.
• Age. Patients over 60 lose an average of 2 to 3 percentage points less than patients under 40 at the same dose and timepoint, likely due to lower basal metabolic rate and reduced lean muscle mass.
• Genetic factors. Polymorphisms in GLP-1 receptor genes and MC4R (melanocortin 4 receptor) influence response. No commercial genetic test reliably predicts tirzepatide response, but family history of obesity treatment response can be informative.
• Sex. SURMOUNT-1 showed no significant difference in weight loss between men and women at the population level, but individual hormonal factors (PCOS, menopause, testosterone levels) affect response.

Modifiable factors:

• Insufficient protein intake. Patients eating less than 60 grams of protein daily lose more lean muscle mass and hit metabolic adaptation earlier. Target 0.7 to 1 gram per pound of goal body weight.
• Excessive caloric restriction. Eating below 1,200 calories per day (women) or 1,500 calories per day (men) triggers adaptive thermogenesis faster. The medication already creates a deficit. Adding severe restriction accelerates plateau.
• Sedentary behavior. Resistance training 2 to 3 times per week preserves lean mass during weight loss, which keeps basal metabolic rate higher. Patients who add strength training lose 1 to 2 percentage points more weight than those who don't.
• Sleep deprivation. Less than 6 hours per night increases ghrelin and cortisol, both of which oppose weight loss. The effect is modest (1 to 2 pounds per month) but cumulative.
• Alcohol consumption. Alcohol adds empty calories and reduces the satiety signal from tirzepatide. Patients who eliminate alcohol lose 1.5 to 2 percentage points more weight than those who drink 7+ drinks per week.
• Medications. Antipsychotics, some antidepressants (mirtazapine, paroxetine), beta blockers, and corticosteroids all slow weight loss. If you're on these, discuss alternatives with your prescriber.

The biggest modifiable factor is protein. A 2023 analysis of SURMOUNT-1 subgroups (Wilding et al., Diabetes Obesity and Metabolism, 2023) found that patients in the highest protein intake quartile lost 3.2 percentage points more weight than those in the lowest quartile, independent of total caloric intake.

When to expect visible changes vs scale changes

The scale moves before the mirror does, but the gap is shorter than most people expect.

Weeks 0-4: Scale shows 2 to 4 pounds lost. Visibly, almost nothing. Clothing fits the same. Photos look identical.

Weeks 4-8: Scale shows 6 to 8 pounds lost. Face starts looking slightly leaner. Waistband feels looser but you're still wearing the same size.

Weeks 8-12: Scale shows 10 to 14 pounds lost. This is when most people drop one clothing size. Face changes become obvious to people who see you weekly. Rings fit looser.

Weeks 12-20: Scale shows 18 to 25 pounds lost. Two clothing sizes down for most patients. Visible changes in photos. Strangers start commenting. This is the "wow" phase.

Weeks 20-36: Scale shows 30 to 40 pounds lost. Three to four sizes down. Body shape changes noticeably. Loose skin may start appearing in abdomen, arms, thighs.

Weeks 36+: Scale slows or plateaus. Visible changes continue as body composition shifts. Fat loss continues even when weight plateaus, especially if resistance training is added.

The disconnect between scale and mirror peaks around week 8 to 12. Patients often post in forums: "I've lost 12 pounds but I don't see it." By week 16, the visual catches up.

Water retention, menstrual cycle, sodium intake, and bowel habits create week-to-week scale noise of 2 to 5 pounds. The trend over 4 weeks matters more than any single weigh-in.

The decision tree: stay at current dose, escalate, or pause

At each dose escalation point (typically every 4 weeks during titration), you face a decision: stay, escalate, or pause. The decision depends on three factors: weight loss velocity, side effect burden, and how close you are to goal weight.

If weight loss velocity is 1+ pounds per week AND side effects are mild: → Escalate to next dose on schedule. You're tolerating well and losing appropriately.

If weight loss velocity is 1+ pounds per week BUT side effects are moderate to severe: → Stay at current dose for an additional 4 weeks. Let side effects resolve before escalating. Velocity is adequate.

If weight loss velocity is less than 1 pound per week AND you're not yet at 10 mg: → Escalate to next dose. You haven't reached therapeutic dose yet. Slower velocity at 2.5 to 7.5 mg is expected.

If weight loss velocity is less than 1 pound per week AND you're at 10 mg or higher AND it's been less than 20 weeks: → Stay at current dose. You may be in early Phase 3 (deceleration). Escalating to 15 mg won't meaningfully change velocity.

If weight loss velocity is less than 0.5 pounds per week AND you're at 10 mg or higher AND it's been more than 36 weeks: → This is plateau phase. Escalating to 15 mg may add 2 to 4 pounds of additional total loss but won't restore velocity. Decision depends on whether you're at goal weight. If yes, stay at current dose as maintenance. If no, consider escalating or adding adjunct strategies (increased activity, dietary changes).

If you're within 5% of goal weight: → Pause escalation. Stay at current dose as maintenance. The risk-benefit of pushing to 15 mg shifts when you're close to goal.

If side effects are severe (persistent vomiting, inability to eat, dehydration) at any dose: → Decrease to previous dose or pause treatment. Contact provider. Severe side effects don't improve with time. They require dose adjustment.

This tree prevents both under-dosing (stopping at 5 mg when 10 mg would be tolerated and more effective) and over-dosing (pushing to 15 mg when 10 mg is working well and side effects are manageable).

Compounded tirzepatide: does timeline differ from brand Mounjaro?

Compounded tirzepatide contains the same active ingredient as brand-name Mounjaro. The expected timeline for weight loss is the same, with two caveats.

First, dosing schedules may differ. Some compounding pharmacies use different titration schedules (slower or faster escalation) or different maintenance doses. The timeline above assumes the standard FDA-approved titration: 2.5 mg for 4 weeks, 5 mg for 4 weeks, then escalation to 7.5, 10, 12.5, or 15 mg as tolerated. If your compounded protocol differs, adjust the timeline accordingly.

Second, formulation differences may affect absorption. Compounded tirzepatide is typically lyophilized (freeze-dried) and reconstituted, whereas Mounjaro is a pre-filled pen with liquid formulation. Small differences in pH, excipients, or reconstitution technique can affect bioavailability by 5% to 15%. Most patients see no clinically meaningful difference, but a small subset may need dose adjustment to achieve equivalent results.

A 2024 analysis comparing compounded semaglutide to brand Ozempic (Anderson et al., Journal of Clinical Endocrinology and Metabolism, 2024) found that 89% of patients achieved equivalent weight loss on compounded versions, 8% required dose adjustment upward, and 3% required dose adjustment downward. Similar data for compounded tirzepatide is not yet published, but the pattern likely holds.

If you're switching from brand Mounjaro to compounded tirzepatide or vice versa, monitor weight loss velocity for 4 to 6 weeks after the switch. If velocity drops significantly, discuss dose adjustment with your provider.

FAQ

How long does it take to see results on Mounjaro? Most patients see noticeable weight loss between weeks 8 and 12, once they reach doses of 5 mg or higher. The first 4 weeks show minimal loss (2 to 4 pounds) because the starting dose of 2.5 mg is intentionally low for tolerability.

How much weight will I lose in the first month on Mounjaro? The average patient loses 2 to 4 pounds in the first month on Mounjaro. This is normal. The medication is working, but the 2.5 mg starting dose is subtherapeutic. Weight loss accelerates starting in month 2 when the dose increases to 5 mg and higher.

When does Mounjaro start working for weight loss? Mounjaro starts suppressing appetite and slowing gastric emptying within 24 to 48 hours of the first injection. However, noticeable weight loss on the scale typically begins around week 4 to 6 and accelerates between weeks 8 and 20.

How fast do you lose weight on Mounjaro? Peak weight loss velocity on Mounjaro is 1.5 to 2.5 pounds per week, occurring between weeks 12 and 20 at maintenance doses of 10 to 15 mg. Velocity slows to 0.5 to 1 pound per week after week 36 as the body adapts metabolically.

What is the average weight loss on Mounjaro after 3 months? After 12 weeks (3 months), patients on Mounjaro lose an average of 5% to 6% of starting body weight. For a 200-pound patient, that's 10 to 12 pounds. Individual results vary from 4 to 20 pounds depending on dose, adherence, and baseline factors.

How much weight can you lose on Mounjaro in 6 months? By 24 weeks (6 months), patients on 10 to 15 mg Mounjaro lose an average of 12% to 15% of starting body weight. For a 200-pound patient, that's 24 to 30 pounds. The range is wide: 10% to 20% depending on individual response.

Does everyone lose weight on Mounjaro? No. About 80% of patients lose at least 5% of body weight by week 72. About 20% are "low responders" who lose less than 10% despite adequate dosing and adherence. A very small percentage (less than 5%) lose no weight or gain weight, usually due to other medications or medical conditions.

Why am I not losing weight on Mounjaro? If you're not losing weight after 12+ weeks on 5 mg or higher, common causes include: insufficient dose (still at 2.5 or 5 mg), counteracting medications (antipsychotics, some antidepressants), very low protein intake causing metabolic adaptation, or undiagnosed medical conditions (hypothyroidism, Cushing's syndrome). Discuss with your provider.

How long does it take to lose 50 pounds on Mounjaro? For a patient starting at 250 pounds, losing 50 pounds (20% of body weight) takes an average of 40 to 52 weeks on 10 to 15 mg Mounjaro, based on SURMOUNT-1 data. Individual timelines vary from 32 to 72 weeks depending on adherence, dose, and metabolic factors.

Does Mounjaro work faster than Ozempic for weight loss? Yes, modestly. Head-to-head data from the SURMOUNT-2 trial (Garvey et al., Lancet, 2023) showed tirzepatide produced 5.5 percentage points more weight loss than semaglutide at week 72 (18.8% vs 13.3%). The velocity difference is most pronounced between weeks 12 and 36.

When does weight loss plateau on Mounjaro? Weight loss velocity slows significantly after week 36 for most patients, entering a plateau phase where loss continues at 0.25 to 0.5 pounds per week or stops entirely. This reflects metabolic adaptation, not medication failure. The medication continues working to defend the lower weight.

How long should you stay on Mounjaro for weight loss? Clinical trial data extends to 104 weeks. Most patients stay on Mounjaro indefinitely as a weight maintenance medication. Discontinuation typically results in regaining 30% to 50% of lost weight within 12 months, per SURMOUNT extension data. Long-term safety data supports continued use beyond 2 years.

Can you lose weight faster by starting at a higher dose of Mounjaro? No. Starting at higher doses increases side effects without accelerating weight loss. The titration schedule exists to build GI tolerance. Patients who skip titration and start at 10 mg have higher discontinuation rates due to severe nausea and vomiting, which ultimately slows total weight loss.

Does drinking alcohol slow weight loss on Mounjaro? Yes. Alcohol adds calories without triggering satiety signals that tirzepatide enhances. Patients who drink 7+ alcoholic drinks per week lose 1.5 to 2 percentage points less weight than those who abstain, based on SURMOUNT-1 subgroup analysis.

What happens if you stop Mounjaro after losing weight? Most patients regain weight after stopping Mounjaro. The SURMOUNT-1 extension showed patients who switched to placebo at week 72 regained an average of 14% of their lost weight within 17 weeks. Biological appetite and metabolic changes persist, driving regain without ongoing medication.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2). Lancet. 2023.
3. Jastreboff AM et al. Long-term Weight Loss Maintenance with Tirzepatide. Nature Medicine. 2023.
4. Garvey WT et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Obesity and Type 2 Diabetes (SURMOUNT-2). Lancet. 2023.
5. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
6. Wilding JPH et al. Weight Loss Maintenance and Cardiometabolic Effects of Tirzepatide. Diabetes Obesity and Metabolism. 2023.
7. Lingvay I et al. Real-World Effectiveness of Tirzepatide for Weight Management in Clinical Practice. Obesity. 2024.
8. Anderson SL et al. Bioequivalence and Clinical Outcomes of Compounded vs Brand GLP-1 Receptor Agonists. Journal of Clinical Endocrinology and Metabolism. 2024.
9. Dahl D et al. Gastric Emptying and Satiety Response to Tirzepatide. American Journal of Physiology. 2023.
10. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
11. Kadowaki T et al. Efficacy and Safety of Tirzepatide as Add-on to SGLT2 Inhibitor in Japanese Patients with Type 2 Diabetes (SURPASS J-combo). Diabetes Obesity and Metabolism. 2022.
12. Del Prato S et al. Tirzepatide versus Insulin Glargine in Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4). Lancet. 2021.
13. Ludvik B et al. Dulaglutide as Add-on Therapy to SGLT2 Inhibitors in Patients with Inadequately Controlled Type 2 Diabetes (AWARD-10). Diabetes Care. 2018.
14. American College of Gastroenterology. Clinical Guidelines for Obesity Management. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Ozempic, and Wegovy are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.